YIN Dali
Principal Investigator
Professor Yin Dali graduated from Nanking College of Pharmacy in 1982 and received his bachelor's degree in medicinal chemistry. He received his master degree and Ph.D degree from the Institute of Materia Medica, Chinese Academy of Medical Sciences in 1988 and 1998 respectively. During this time, he had working experience in the University of Connecticut in US and Taisho Pharmaceuticals in Japan. He has been devoted himself to new drug discovery and development for more than 30 years. He worked in the fields including anti-anxiolytics, anti-tuberculosis, autoimmune, and anticancer drugs. Totally four drug candidates have been forwarded into clinical trials in different stages. Buagarofuran is a sesquiterpine compound derived from natural agarofuran. It is the first time to find this kind of compounds with anti-anxiolytic activity.
1. Assessing the ligand selectivity of sphingosine kinases using molecular dynamics and MM-PBSA binding free energy calculations. Mol. BioSyst., 2016, 12:1174-1182.
2. Assembly of substituted phenanthridines via a cascade palladium-catalyzed coupling reaction, deprotection and intramolecular cyclization. RSC Adv. , 2016, 6:19571-19575.
3. Synthesis, identification, and biological activity of metabolites of two novel selective S1P1 agonists. Med. Chem. , 2016, 24:2273-2279.
4. Development of 3-alkyl-6-methoxy-7-hydroxychromones (AMHCs) from natural isoflavones, a new class of fluorescent scaffolds for biological imaging. Chem. Commun., 2015,51:881
5. Synthesis of Dihydrobenzoheterocycles through Al(OTf)3-Mediated Cascade Cyclization and Ionic Hydrogenation. Journal of Organic Chemistry , 2014,79:9678-9685.
6. Highly Efficient and Versatile Synthesis of Lactams and N-Heterocycles via Al(OTf)3-Catalyzed Cascade Cyclization and Ionic Hydrogenation Reactions. Organic Letters , 2014,16:190-192.
7. Discovery of oxazole and triazole derivatives as potent and selective S1P1 agonists through pharmacophore-guided design. European Journal of Medicinal Chemistry , 2014,85:1-15.
8. Development of a selective S1P1 receptor agonist, Syl930, as a potential therapeutic agent for autoimmune encephalitis. Biochemical Pharmacology , 2014, 90:50-61.
9. Design, synthesis and docking-based 3D-QSAR study of novel 2-substituted 2-aminopropane-1,3-diols as potent and selective agonists of sphingosine-1- phosphate 1 (S1P1) receptor. Med. Chem. Commun. , 2013, 4:1267-1274.
